|Brief Description||Principal Investigator|
|The primary objective of this study is to evaluate safety and tolerability and select a recommended Phase 2 dose (RP2D) of ADXS31-164 in subjects with solid tumors that express HER2||Tan, Antoinette Roslyn|
|To describe the anti-tumor activity (efficacy) and toxicity (safety) of commercially available, targeted anti-cancer drugs used for treatment of patients with advanced solid tumors, multiple myeloma or B cell non-Hodgkin lymphoma with a genomic variant known (i) to be a target of an FDA-approved anti-cancer drug or (ii) to predict sensitivity to an FDA-approved anti-cancer drug.||Kim, Edward Sanghyun|
|To investigate the safety and tolerability of selumetinib when given in combination with MEDI4736 to patients with advanced solid malignancies.||Kim, Edward Sanghyun|
|In the neoadjuvant cohort, to investigate the safety and tolerability of neoadjuvant nivolumab administration in the following tumor types: HPV-positive (SCCHN), HPV-negative (SCCHN), Merkel Cell Carcinoma, Cervical, vaginal, or vulvar cancers. In the metastatic/recurrent cohort, to evaluate the investigator-assessed objective response rate (ORR) of nivolumab monotherapy in subjects with the following diseases: Metastatic or recurrent nasopharyngeal carcinoma (NPC); Metastatic or Recurrent EBV r||Amin, Asim|
I. To maintain a Childhood Cancer Registry for infants, children, adolescents, and young adults with cancer.
II. To utilize clinical and biological data to help determine eligibility or stratification, based on childhood cancer disease classification schemas, for potential enrollment of research subjects onto Children's Oncology Group (COG) therapeutic clinical trials.
III. To develop a well annotated childhood cancer biobank for current and future research through the collection of biospe
|Kaplan, Joel Adam|
|Estimate PFS in previously untreated mCRC patients receiving FOLFIRI + bevacizumab when irinotecan dose is based on UGT1A1 genotype||Patel, Jai Narendra|
|To identify subpopulations of registry patients on the basis of their molecular profiles that may be eligible for participation in available NSABP clinical trials involving novel agents.||Hwang, Jimmy John|
|To describe the long term safety, and clinical outcomes of aflibercept in combination with FOLFIRI in patients treated in daily practice for a metastatic CRC after failure of an oxaliplatin-based regimen.||Nazemzadeh, Reza|